CDK4/6i in HR+ SABCS 2022 Highlights - OncBrothers (Rohit and Rahul Gosain) with Dr. Sara Tolaney

preview_player
Показать описание
Discussing CDK4/6i utilization in Hormone Receptor Positive (HR+) Highlights from SABCS 2022 on usage of CDK4/6 inhibitors - Practice changing studies with Dr. Sara Tolaney, Chief - Division of Breast Oncology at Dana-Farber and Associate Professor at Harvard Medical School

#hr+ #sabcs #saratolaney #cdk4/6i #treatment #algorithm #cancer #2023 #oncology #onbrothers #DrJarushkaNaidoo #targetablemutations #lungcancer #lungcancerawareness #lungcancertreatment

  1. OncBrothers: Practice-Changing Cancer Discussions
  2. practicechanging
  3. cancer
  4. oncology
  5. 2022
  6. ctdna
Рекомендации по теме
CDK4/6i in HR+ 0:14:40

CDK4/6i in HR+ SABCS 2022 Highlights - OncBrothers (Rohit and Rahul Gosain) with Dr. Sara Tolaney

Remaining questions on 0:01:12

Remaining questions on the use of frontline CDK4/6 inhibitors + endocrine therapy

The use of 0:02:11

The use of frontline CDK4/6 inhibitors + endocrine therapy in metastatic breast cancer

Biomarkers to help 0:01:04

Biomarkers to help predict response to CDK4/6 inhibitors

Update of EMERALD 0:00:46

Update of EMERALD by duration of CDK4/6i in metastatic setting: elacestrant v SoC in ER+/HER2- mBC

Investigating mechanisms of 0:00:50

Investigating mechanisms of resistance to CDK4/6 inhibitors

Dr. Rinath Jeselsohn 0:56:01

Dr. Rinath Jeselsohn | Demystifying CDKs in Breast Cancer Beyond CDK46 | SABCS 2022

Updated results by 0:02:21

Updated results by duration of prior CDK4/6i in the met setting of the Phase III EMERALD trial

TAKTIC: ipatasertib, endocrine 0:02:07

TAKTIC: ipatasertib, endocrine therapy and CDK4/6i for patients with HR+/HER2- mBC

ASCO 2022/Brustkrebs: Ist 0:06:39

ASCO 2022/Brustkrebs: Ist eine Dosisreduktion der CDK4/6-Therapie bei Nebenwirkungen möglich?

CDK4/6 for HR+ 0:03:24

CDK4/6 for HR+ early breast cancer: monarchE results

Educational Sessions: 'CDK4/6 0:21:35

Educational Sessions: 'CDK4/6 for ER+'

SABCS 2022 takeaways 0:02:00

SABCS 2022 takeaways

The impact of 0:00:30

The impact of the EMERALD trial results based on duration of prior CDK4/6i in the metastatic setting

ESMO 2020 Expert 0:05:32

ESMO 2020 Expert Video Report on CDK4 6i in the adjuvant treatment of breast cancer

Raising the Bar 1:09:24

Raising the Bar in HR+/HER2- Early Breast Cancer: CDK4 and 6 Inhibitors

Adjuvant CDK4/6 inhibition 0:06:36

Adjuvant CDK4/6 inhibition in early-stage HR-positive breast cancer | Ruth O'Regan

SABCS 2022 highlights 0:01:06

SABCS 2022 highlights

Webinar on MANAGEMENT 0:52:18

Webinar on MANAGEMENT OF MBC - CDK4/6 INHIBITORS

SABCS 2022: Updated 0:12:19

SABCS 2022: Updated survival results of the randomized, phase 3 study DESTINY-Breast03 + Q & A

Maintenance w/ ET 0:00:36

Maintenance w/ ET + ribociclib after 1L chemotherapy in HR+/HER2- metastatic breast cancer

Key highlights from 0:00:55

Key highlights from SABCS 2022

Key trial updates 0:01:17

Key trial updates in SERDs in ER+/HER2- breast cancer from SABCs 2022

Key data from 0:02:57

Key data from the San Antonio Breast Cancer Symposium (SABCS) 2022